Business Context and Reporting Period
The filing is a Form 10-Q for the three months ended March 31, 2020, filed May 15, 2020. Although the request metadata identifies Palisade Bio, Inc., the provided filing identifies the registrant as Seneca Biopharma, Inc. (formerly Neuralstem, Inc.), ticker SNCA.
Seneca is a clinical-stage biopharmaceutical company developing neural stem-cell and small-molecule therapies, including NSI-566 and NSI-189. The company is pursuing out-licensing and in-licensing or acquisition opportunities and has not generated revenue from commercial product sales.
Financial Highlights
| Metric | Q1 2020 | Q1 2019 | Change |
|---|---|---|---|
| Revenue | $6,020 | $2,500 | +$3,520 |
| Research and development | $696,889 | $1,514,463 | -54% |
| General and administrative | $1,299,595 | $944,602 | +38% |
| Total operating expenses | $1,996,484 | $2,459,065 | -19% |
| Operating loss | $1,990,464 | $2,456,565 | Improved by $466,101 |
| Net loss | $7,575,218 | $3,113,992 | Worsened by $4,461,226 |
| Basic and diluted loss per share | $0.93 | $3.42 | Improved per share due primarily to share issuance |
| Net cash used in operating activities | $1,677,629 | $1,665,905 | Approximately flat |
| Cash and cash equivalents at period-end | $10,030,024 | $4,005,089 | +150% |
Revenue consisted of $2,500 in ongoing intellectual-property license fees and $3,500 in royalty revenue related to a prior patent-infringement settlement. Revenue represented less than 1% of operating expenses, and the company has no commercial product revenue.
The company reported total assets of $11.4 million, total liabilities of $1.4 million, and stockholders’ equity of $10.0 million at March 31, 2020. Current liabilities were $1.2 million. The filing reports no material long-term borrowings; liabilities primarily consisted of accounts payable and accrued expenses, warrant liabilities, short-term obligations, and lease liabilities.
Material Changes Versus the Prior Comparable Period
- R&D expense declined $817,574, or 54%, primarily because clinical activities for the stem-cell and small-molecule programs were being wound down.
- G&A expense increased $354,993, or 38%, reflecting an enhanced management and consulting structure associated with the company’s strategic shift toward out-licensing and evaluating new assets.
- Net loss increased substantially because Q1 2020 included a non-cash warrant-inducement expense of approximately $5.6 million. Q1 2019 instead included a related-party receivable write-off and a warrant fair-value loss.
- In January 2020, holders exercised 5,555,554 warrants at $1.36 per share, generating approximately $6.7 million of net proceeds. The company issued an equal number of replacement warrants with a $1.23 exercise price, plus placement-agent warrants.
- Common shares outstanding increased from 3,866,457 at December 31, 2019 to 9,428,011 at March 31, 2020. Approximately 8.5 million shares were reserved for equity awards and outstanding equity-linked instruments.
- Cash increased by approximately $4.9 million during the quarter, primarily because warrant-exercise proceeds exceeded operating cash usage.
Guidance, Outlook, Risks, and Unusual Items
- Management expects existing cash to fund anticipated operations for more than 12 months after the filing, but states that additional capital will be required to advance product candidates, conduct clinical and preclinical programs, pursue acquisitions or licensing transactions, and fund operations.
- The financial statements disclose substantial doubt regarding the company’s ability to continue as a going concern. Management has no committed future funding and may need to raise equity or debt capital, enter collaborative or licensing arrangements, or sell assets.
- If financing is unavailable, the company may delay, reduce, or terminate research and clinical programs, license assets on unfavorable terms, cease operations, or seek bankruptcy protection.
- COVID-19 had not yet produced a determinable material short-term impact, but management warned that prolonged shutdowns could delay clinical trials, increase vendor and development costs, and impair access to capital.
- Nasdaq notified the company that its common stock did not meet the $1.00 minimum bid-price requirement. The filing states that the compliance deadline was extended to December 10, 2020, subject to potential further remedies or delisting.
- The company’s principal programs remain early-stage and subject to clinical-trial failure, regulatory rejection, manufacturing and supplier risks, intellectual-property challenges, and reliance on third parties.
- The NSI-189 Phase 2 trial in major depressive disorder did not meet its primary efficacy endpoint, although certain secondary and cognitive measures showed reported improvements.
- The company reported no legal proceedings, no investing cash flows, and no subsequent events through the date of the financial statement review.
Investor Verification Checklist
- Verify the registrant identity: the supplied filing is for Seneca Biopharma, Inc., not Palisade Bio, Inc.
- Reconcile cash runway assumptions with the approximately $1.7 million quarterly operating cash burn and the company’s stated need for additional financing.
- Assess dilution from 9.4 million issued common shares, approximately 7.4 million outstanding warrants, preferred-stock conversion rights, options, and other reserved shares.
- Review the $5.6 million non-cash warrant-inducement charge and the terms, expiration dates, and anti-dilution provisions of the replacement and legacy warrants.
- Monitor Nasdaq minimum-bid compliance and the risk of delisting.
- Evaluate clinical status, data quality, regulatory pathway, and funding requirements for NSI-566, NSI-189, and any future in-licensed or acquired programs.
- Review the going-concern disclosure, available financing alternatives, and the absence of committed future funding.